Weinberger Asset Management Inc Sells 1,693 Shares of Pfizer Inc. $PFE

by · The Cerbat Gem

Weinberger Asset Management Inc reduced its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 10.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,115 shares of the biopharmaceutical company’s stock after selling 1,693 shares during the quarter. Weinberger Asset Management Inc’s holdings in Pfizer were worth $366,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the first quarter valued at $27,000. North Capital Inc. purchased a new stake in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer during the fourth quarter valued at $30,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PFE shares. Bank of America upped their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Jefferies Financial Group upped their price target on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, May 21st. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Berenberg Bank reduced their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Finally, Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $28.12.

Check Out Our Latest Stock Analysis on PFE

Pfizer Price Performance

Shares of Pfizer stock opened at $24.03 on Thursday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $136.62 billion, a P/E ratio of 12.78, a PEG ratio of 0.85 and a beta of 0.55. The business has a 50 day simple moving average of $24.70 and a two-hundred day simple moving average of $24.25.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the firm earned $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).